LakeShore Biopharma (LSB) AI Stock Analysis

• Market Cap: $34.37M
• Dividend Yield: N/A
• Average Volume (3M): 58.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 758
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 41,212,692
• 10 Day Avg. Volume: 38,185
• 30 Day Avg. Volume: 58,070
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.00
• Price Target Upside: 20.48% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: $1.00 ▲(20.48% Upside)

The overall stock score is primarily influenced by the company's financial performance challenges, including persistent losses and negative cash flows. Technical analysis indicates a bearish trend, further impacting the score. The lack of valuation metrics such as P/E ratio and dividend yield also contributes to the low score.

Positive Factors

Strong Gross Profit Margins

High gross profit margins indicate strong product profitability, suggesting that the company effectively manages production costs and pricing strategies, which is essential for long-term financial health.

Improved Leverage Management

Better leverage management reflects improved financial discipline, reducing financial risk and enhancing the company's ability to invest in growth opportunities.

Strategic Partnerships

Strategic partnerships provide significant upfront payments and royalties, diversifying revenue streams and enhancing long-term financial stability.

Negative Factors

Persistent Losses

Ongoing losses and negative cash flows indicate operational inefficiencies, which could hinder the company's ability to invest in growth and innovation, impacting long-term sustainability.

Negative Cash Flow

Negative cash flows highlight liquidity challenges, limiting the company's ability to fund operations and strategic initiatives without external financing.

High Debt Levels

High debt levels can strain cash flow and limit financial flexibility, posing risks to long-term stability and growth potential.

LakeShore Biopharma Business Overview & Revenue Model

Company Description

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

How the Company Makes Money

LakeShore Biopharma generates revenue primarily through the commercialization of its therapeutic products, which include sales of approved drugs and biologics. The company also engages in strategic partnerships and collaborations with larger pharmaceutical companies for co-development and licensing agreements, which provide significant upfront payments and ongoing royalties based on product sales. Additionally, LSB may receive funding through government grants and research contracts aimed at advancing its clinical trials and product development efforts. The combination of direct product sales, royalties from partnerships, and external funding sources contributes to LSB's overall revenue stream.

LakeShore Biopharma Financial Statement Overview

Summary

LakeShore Biopharma exhibits strong gross profit margins, but persistent losses and negative cash flows pose significant challenges. The company needs to focus on improving operational efficiency and profitability to enhance its financial health. While leverage management has improved, further efforts are required to stabilize cash flows and achieve sustainable growth.

Income Statement

LakeShore Biopharma shows a consistent gross profit margin above 75%, indicating strong product profitability. However, the company faces challenges with negative net profit margins and EBIT margins, reflecting ongoing losses. Revenue growth is positive, but the company needs to address its high operating losses to improve overall profitability.

Balance Sheet

The company's debt-to-equity ratio has improved over time, indicating better leverage management, yet it remains relatively high. The negative return on equity highlights ongoing profitability challenges. The equity ratio suggests a moderate reliance on equity financing, but the company needs to enhance its asset utilization and profitability.

Cash Flow

LakeShore Biopharma's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is positive, indicating some efficiency in converting net income to cash, but the overall negative cash flow growth and coverage ratios highlight liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	577.33M	614.96M	573.42M	687.20M	502.95M	257.02M
Gross Profit	389.12M	507.19M	455.73M	533.84M	385.88M	197.36M
EBITDA	-315.55M	-48.54M	-368.66M	-76.80M	-67.20M	-116.78M
Net Income	-436.09M	-99.98M	-433.46M	-145.48M	-545.73K	-191.83M
Balance Sheet
Total Assets	1.51B	1.37B	1.51B	1.72B	201.03M	91.37K
Cash, Cash Equivalents and Short-Term Investments	246.35M	28.08M	246.35M	370.11M	885.20K	390.46M
Total Debt	424.46M	414.40M	424.46M	498.63M	380.59M	5.01K
Total Liabilities	927.82M	867.91M	927.82M	991.30M	20.35M	70.01K
Stockholders Equity	585.21M	499.75M	585.21M	728.45M	180.68M	21.36K
Cash Flow
Free Cash Flow	0.00	-138.84M	-339.48M	-239.52M	-299.55M	-351.49M
Operating Cash Flow	0.00	-120.98M	-295.23M	-182.47M	-613.23K	-246.61M
Investing Cash Flow	0.00	-17.01M	-44.25M	-56.98M	-200.00M	-104.24M
Financing Cash Flow	0.00	-3.58M	205.26M	317.45M	201.50M	739.26M

LakeShore Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSB, the sentiment is Negative. The current price of 0.83 is above the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.91, and below the 200-day MA of 1.76, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 47.99 is Neutral, neither overbought nor oversold. The STOCH value of 80.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSB.

LakeShore Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	53 Neutral	$85.54M	―	1063.61%	―	202.41%	98.99%
Sector *	51 Neutral	$7.90B	-0.36	-43.38%	2.23%	22.34%	-2.15%
HOWL	48 Neutral	$64.48M	―	-100.55%	―	-100.00%	-22.09%
CASI	46 Neutral	$36.41M	―	-1094.50%	―	41.43%	-50.12%
NRXP	45 Neutral	$70.60M	―	108.28%	―	―	18.51%
LSB	42 Neutral	$34.37M	―	-74.07%	―	―	―
RADX	―	$45.20M	―	-100.72%	―	―	―